Search results for "C1 esterase inhibitor"

showing 5 items of 5 documents

Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week

2009

<i>Background:</i> Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is characterized by recurrent edema attacks in various organs. The objective of the present study was to assess the efficacy and safety of weekly long-term replacement treatment with one or more injections of plasma-derived C1-INH concentrate per week (WLTC) in patients with HAE-C1-INH. <i>Methods:</i> Nineteen patients with HAE-C1-INH underwent WLTC for 9 years on average. The benefits and risks were determined based on regular recording by the patients of the severity and number of attacks at the beginning and the end of the study. <i>Results:</i> All patients reported …

AdultMalemedicine.medical_specialtyLong term treatmentC1 inhibitor deficiencyImmunologyBradykininGastroenterologyDrug Administration ScheduleC1-inhibitorEdemaInternal medicineHumansImmunology and AllergyMedicineProspective Studiesskin and connective tissue diseasesBradykinin Receptor AntagonistsC1 esterase inhibitor deficiencyAgedbiologyAngioedemabusiness.industryAngioedemas HereditaryGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSurgeryHereditary angioedemaImmunologybiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinInternational Archives of Allergy and Immunology
researchProduct

The complex alteration in the network of IL-17-type cytokines in patients with hereditary angioedema

2018

Hereditary angioedema (HAE) is a rare autosomic-dominant disorder characterized by a deficiency of C1 esterase inhibitor which causes episodic swellings of subcutaneous tissues, bowel walls and upper airways that are disabling and potentially life-threatening. We evaluated n = 17 patients with confirmed HAE diagnosis during attack and remission state and n = 19 healthy subjects. The samples were tested for a panel of IL (Interleukin)-17-type cytokines (IL-1β, IL-6, IL-10, granulocyte–macrophage colony stimulating factor (GM-CSF), IL-17, IL-21, IL-22, IL-23) and transforming growth factor-beta (TGF-β) subtypes. Data indicate that there are variations of cytokine levels in HAE subjects compar…

Male0301 basic medicinemedicine.medical_treatmentC1 esterase inhibitorInterleukin-23chemistry.chemical_compoundSubcutaneous TissueTransforming Growth Factor betaChildHereditary angioedemaHematologyInterleukin-17InterleukinGeneral MedicineMiddle AgedIntestinesCytokineHereditary angioedemaFemaleInterleukin 17medicine.symptomComplement C1 Inhibitor ProteinAdultmedicine.medical_specialtyAdolescentBradykininBronchiBradykininGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesInternal medicinemedicineHumansCytokineAgedBiochemistry Genetics and Molecular Biology (all)Angioedemabusiness.industryInterleukinsAngioedemas HereditaryGranulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseColony-stimulating factor030104 developmental biologyGene Expression RegulationchemistryCase-Control StudiesImmunologyTh17 CellsbusinessClinical and Experimental Medicine
researchProduct

Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwentsurgical reperfusion: a randomized double-…

2007

Background: The inflammatory cascade has been hypothesized to be an important mechanism of post-ischaemic myocardial reperfusion injury and several studies demonstrated that C1 esterase inhibitor (C1 -INH) is effective in post-ischaemia myocardial protection. Therefore, we aimed to investigate prospectively in a randomised double-blind study the cardioprotective effects of C1-INH in ST segment elevation myocardial infarction (STEMI) in patients who underwent emergent reperfusion with coronary artery bypass grafting (CABG). Methods: In this study, we enrolled 80 patients affected with STEMI who underwent emergent CABG. Patients were assigned in two groups (C1-INH group: receive 1000 Ul of C1…

MalePulmonary and Respiratory MedicineCardiac function curvemedicine.medical_specialtyMean arterial pressureCardiotonic AgentsMyocardial InfarctionCardiac indexMyocardial ReperfusionComplement C1 Inactivator ProteinsCoronary artery bypass surgeryReperfusion therapyDouble-Blind MethodInternal medicinemedicineHumansProspective StudiesMyocardial infarctionCoronary Artery BypassInfusions IntravenousSTEMI patients CABG C1 esterase inhibitor Reperfusion injury Complement cascade Myocardial function recoverybusiness.industryST elevationTroponin IComplement C4aGeneral MedicineMiddle Agedmedicine.diseaseMyocardial ContractionComplement Inactivating AgentsTreatment OutcomeComplement C3aCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessReperfusion injury
researchProduct

Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency.

2016

Abstract Background Hereditary angioedema (HAE) is a rare disease characterized by C1-esterase inhibitor (C1-INH) deficiency, resulting in periodic attacks of acute edema, which can be life-threatening if they occur in the upper airway. No head-to-head comparisons of different treatment options for acute HAE attacks are available. Because immediate symptom relief is critical for potentially life-threatening laryngeal attacks, it is important to determine the treatment option that provides optimal treatment response. Objective Review and compare data from clinical studies that evaluated the efficacy and safety of treatments for laryngeal HAE attacks. Methods We conducted an indirect comparis…

medicine.medical_specialtyPathologyefficacyLaryngeal Diseases03 medical and health sciencesEcallantidechemistry.chemical_compound0302 clinical medicineSymptom reliefIcatibantInternal medicinemedicineHumans030212 general & internal medicineProspective cohort studyC1 esterase inhibitor deficiencybusiness.industryHAEAngioedemas Hereditarymedicine.diseaselaryngealTreatment Outcome030228 respiratory systemchemistryHereditary angioedemaEmergency MedicineC1-INHre-dosingbusinessAirwayComplement C1 Inhibitor Proteinmedicine.drugRare diseaseThe Journal of emergency medicine
researchProduct

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks: An Open-Label Extension Study …

2018

medicine.medical_specialtybiologybusiness.industryC1 Esterase Inhibitor ProteinExtension studymedicine.diseaseC1-inhibitorInternal medicineHereditary angioedemabiology.proteinLong term outcomesMedicineOpen labelbusinessSSRN Electronic Journal
researchProduct